Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Xeris Biopharma Holdings, Inc. reported full-year 2023 results: revenue $145 million to $165 million. Guidance raised.
- Period
- full-year 2023
- Revenue
- $145 million to $165 million
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
performance, and expectations for the remainder of the year gives us the confidence to tighten our 2023 guidance by raising the low end of the total revenue range to $145 to $165 million from $135 to $165 million; reducing cash utilization range to $57 to $67 million from $57 to $77 million; improving year-end cash range to $55 to $65 million. And, we expect to
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Xeris Biopharma Holdings, Inc. reported the three and six months ended June 30, 2023 results: revenue $38.0M, net income $19.8 million, or $0.14 per share, EPS $0.14 per share. Guidance raised.
- Period
- the three and six months ended June 30, 2023
- Revenue
- $38.0M
- Net income
- $19.8 million, or $0.14 per share
- EPS
- $0.14 per share
- Guidance
- raised
- Result
- reported results
Exact text from the filing
expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- XERIS BIOPHARMA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Achieved record revenue of $38.0M – a 14% increase from prior quarter, and a 50% increase from same period prior year Ended Q2 with over $80M in cash, cash equivalents and short-term investments Tightens
View on SEC.gov